贝瑞基因(000710) - 2021 Q4 - 年度财报

Business Focus and Strategy - The company reported a significant shift in its main business focus from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales since August 10, 2017[19]. - The company primarily engages in high-throughput sequencing technology-based gene testing services and equipment sales, establishing a strong position in the medical products and services sector[32]. - The company is expanding its product offerings in the field of reproductive health and genetic disease detection, with a focus on comprehensive prenatal screening and diagnosis[32]. - The company aims to establish a comprehensive genetic disease detection product line covering prenatal, pregnancy, and newborn stages to reduce birth defect rates in China[109]. - The company is focused on integrating clinical business with health big data development, aiming to enhance its product and service offerings in the future[50]. - The company is strategically positioned to leverage advancements in tumor detection and personalized medicine through its investments in related technologies and services[110]. - The company is committed to innovation in genetic testing technologies, focusing on both second and third-generation sequencing platforms to meet evolving market demands[111]. Financial Performance - The company's operating revenue for 2021 was ¥1,422,180,921.29, a decrease of 7.67% compared to ¥1,540,385,732.47 in 2020[6]. - The net profit attributable to shareholders was -¥110,818,562.80, representing a decline of 152.60% from a profit of ¥210,665,188.77 in 2020[6]. - The net profit after deducting non-recurring gains and losses was -¥130,200,103.28, a decrease of 213.70% compared to ¥114,509,221.95 in 2020[6]. - The total assets at the end of 2021 were ¥3,519,721,822.69, an increase of 8.50% from ¥3,243,969,209.24 at the end of 2020[6]. - The gross profit margin for the gene testing industry was 44.73%, down 7.89% compared to the previous year[70]. - The company achieved total revenue of 1.422 billion yuan, a decrease of 7.67% compared to the previous year[67]. - Clinical business revenue was approximately 938 million yuan, down 6.90% year-on-year, primarily due to declining service prices and unstable hospital patient volumes[59]. Research and Development - The company has maintained strong research and development capabilities to adapt to market demands and technological advancements[115]. - R&D investment increased by 3.02% to ¥133,265,778.37 in 2021, accounting for 9.37% of operating revenue[81]. - The company has established over 40 types of research service products to meet unique experimental requirements in various fields, including disease research and single-cell research[40]. - The company has developed the Cruxome exome data analysis system, allowing clients to easily input and analyze years of case data, enhancing database usability with AI-driven features[45]. Market Position and Competition - The gene sequencing industry in China has entered a rapid development phase since the release of the "13th Five-Year Plan for the Development of the Biotechnology Industry" in 2017, with increasing recognition of the importance of gene sequencing for precise diagnosis and treatment of diseases[31]. - Increased competition in the gene sequencing market may lead to price reductions, necessitating continuous improvement in service quality and technological advancements[112]. - The company is leveraging its first-mover advantage in the NIPT project to diversify its gene testing services and products, establishing a competitive edge in the market[32]. Corporate Governance and Management - The company emphasizes the independence of its operations from its controlling shareholders to avoid conflicts of interest and ensure fair business practices[123]. - The company has established a comprehensive gene sequencing solution through self-developed reagents, software, and a direct sales network, positioning itself as a pioneer in the rapidly growing gene sequencing industry[47]. - The company has implemented effective financial supervision and internal control systems, allowing for independent financial decision-making[125]. - The company has a low turnover rate among its core team, with 81% of employees holding advanced degrees, ensuring a stable and skilled workforce[54]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[4]. - The company faces risks related to policy changes in the healthcare sector, which could impact operational strategies and market conditions[112]. - The company is committed to maintaining a strict internal governance structure to manage risks associated with its expanding operational scale[121]. - Accounts receivable are increasing rapidly as the company expands, which may lead to cash flow issues if not managed effectively[115]. Product Development and Innovation - The company launched a new product, "Thalassemia Carrier Screening" using third-generation sequencing technology, which significantly improves the efficiency of controlling severe thalassemia and enhances clinical genetic counseling[32]. - The company has launched the clinical-grade liver cancer early screening product "Liver Screening," transitioning its tumor business from late-stage detection to early detection[37]. - The company is in the clinical trial phase for the Sequel II CNDx platform, which is primarily used for thalassemia gene detection[36]. Shareholder Relations and Dividends - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves for the year[5]. - The company has not proposed any cash dividend distribution for the reporting period despite having positive distributable profits[147]. Strategic Partnerships and Collaborations - The company has formed strategic partnerships with leading cloud data providers Huawei Cloud and Alibaba Cloud to offer a complete automated delivery solution from sequencing to cloud[38]. - The company has initiated strategic collaborations with major hospitals to create a more efficient network for genetic disease screening and diagnosis[110]. Environmental and Social Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[163]. - There were no significant environmental protection issues reported, and the company is not classified as a key pollutant discharge unit[163].